On page 10, line 18, after "of the", delete "indentations," and after "pores", delete "or interstices".

At page 11, line 14, after "average", delete "indentation cavity or".

At page 16, line 10, delete "openings, indentations or".

IN THE CLAIMS:

Cancel all of the Claims in the parent application, without prejudice, and substitute the following new claims 92-120:

92. An injectable micro-implantation system for long-term augmentation of soft tissue, comprising in combination:

an amount of generally soft, malleable, elastic, biologically compatible prosthetic micro particles dispersed in a non-retentive compatible physiological vehicle, the micro particles being further characterized by a rough surface texture having a plurality of surface irregularities generally randomly formed therein;

the textured micro particles having a combination of average particle size and average particle texture which cooperate in an autogenous manner to substantially prevent loss of the prosthetic particles from an augmentation site, the particles remaining to be incorporated as part of a permanent implant.

93. An injectable micro-implantation system for long-term augmentation of soft tissue, comprising in combination:

biologically compatible micro particles of a relatively soft, resilient, material dispersed in a non-retentive compatible physiological vehicle, the micro particles being further characterized by a textured surface having a plurality of pores generally randomly forming openings therein;

the textured micro particles having an average particle size generally between 30 and 3000 microns with a dimension of the openings formed by the pores within the particles being generally in a range between 10 angstroms and 500 microns;

wherein relative average particle size and average roughness of texture are sufficient in combination to, in an autogenous manner, substantially preclude migration of the particles from an augmentation site, the particles being incorporated in the final implant.

94. The injectable micro-implantation system of Claim 93 wherein the micro particles further comprise an amount of at least one surface modifier to accomplish at least one of assisting in detoxification and promoting tissue ingrowth.

95. The injectable micro-implantation system of Claim 94 wherein the at least one surface modifier is incorporated into the micro particle prior to particle formation.

96. The injectable micro-implantation system of Claim 94 wherein the at least one surface modifier is selected from the group consisting of polyvinyl pyrrolidone, collagen and an hyaluronate.

97. The injectable micro-implantation system of Claim 93 being particularly characterized in that the compatible physiological vehicle is a bodily compatible fluid selected from the group consisting of hydrogels, glucose, starch, silicone fluid, lipid and a hyaluronate.

98. The injectable micro-implantation system of Claim 96 wherein the surface modifier is dispersed in the physiological vehicle.

99. The injectable micro-implantation system of Claim 94 wherein the surface modifier is biologically active.

100. The injectable micro-implantation system of Claim 98 wherein the surface modifier is biologically active.

101. The injectable micro-implantation system of Claim 100 wherein the modifier is selected from the group consisting of fibronectin and cytokines.

102. The injectable micro-implantation system of Claim 94 wherein the modifier is selected from the group consisting of fibronectin and cytokines.

103. The injectable micro-implantation system of Claim 93 being particularly characterized in that the biologically inert

micro particles are formed of bodily compatible solids selected from the group consisting of silicone rubbers, polytetrafluoroethylene, polyethylene, and other biologically inert polymer materials.

104. The injectable micro-implantation system of Claim 103 being particularly characterized in that the biologically inert micro particles are of a generally uniform configuration.

105. The injectable micro-implantation system of Claim 93 being particularly characterized in that the average particle size is at least 80 microns.

106. The injectable micro-implantation system of Claim 103 being particularly characterized in that the average particle size is at least 80 microns.

107. The injectable micro-implantation system of Claim 104 being particularly characterized in that the average particle size is at least 80 microns.

108. The injectable micro-implantation system of Claim 93 being particularly characterized in that the range of average particle size is between 60 microns and 600 microns.

109. The injectable micro-implantation system of Claim 103 being particularly characterized in that the range of average particle size is between 60 microns and 600 microns.

110. The injectable micro-implantation system of Claim 92 being particularly characterized in that the range of average particle size is between 100 microns to 600 microns.

111. The injectable micro-implantation system of Claim 103 being particularly characterized in that the range of average particle size is between 100 microns to 600 microns.

112. The injectable micro-implantation system of Claim 104 being particularly characterized in that the range of average particle size is between 100 microns to 600 microns.

113. The injectable micro-implantation system of Claim 93 being particularly characterized in that the range of average particle size is between about 100 microns and 600 microns.

114. The injectable micro-implantation system of Claim 106 further characterized by micro particles having a textured surface of pores of an average size between about 10 and about 200 microns.

115. The injectable micro-implantation system of Claim 110 further characterized by micro particles having a textured surface of pores of an average size between about 10 and about 200 microns.

116. The injectable micro-implantation system of Claim 105 being particularly characterized in that the biologically inert micro particles are of a generally uniform configuration.

117. The injectable micro-implantation system of Claim 107 wherein the micro particles are generally spherical in shape.

118. A non-migratory injectable micro-implantation system for the long-term augmentation of soft tissue, comprising in combination:

generally soft, resilient biologically inert micro particles dispersed in a non-retentive compatible physiological vehicle, the micro particles being further characterized by a surface texture having a plurality of surface irregularities generally randomly formed therein;

the micro particles having, in combination, an average particle size range and average particle texture such that migration from an injection site is substantially precluded in an autogenous manner and individual particle non-chronic inflammatory scar tissue encapsulation occurs.

119. An injectable micro-implantation system for long-term augmentation of soft tissue, comprising in combination:

generally soft, resilient biologically inert textured micro implant particles of a relatively permanent material dispersed in a non-retentive compatible physiological vehicle, the micro particles being of a generally uniform configuration and being further characterized by a surface texture having a plurality of surface indentations or porosities separated by connective members generally randomly formed therein;

the textured micro implant particles having an average particle size generally between 30 and 3000 microns with dimensions of the surface indentations or porosities within the particles being generally in a range between 10 angstroms and 500 microns; and

wherein average particle size and average texture roughness including the pores are sufficient in combination to, in an autogenous manner, substantially preclude migration of the particles from an injection site and to achieve adequate guidance of fibroblasts such that a scar tissue pattern is developed that assumes a configuration that is generally in accordance with the surface of the textured micro particle.

120. An injectable micro-implantation system for long-term augmentation of soft tissue, comprising in combination:

generally soft, malleable, resilient biologically compatible relatively permanent prosthetic micro particles dispersed in a non-retentive compatible physiological vehicle, the micro particles being further characterized by a surface having at least a minimum amount of roughness;

the micro particles having an average particle size generally above 80 microns and up to 3000 microns with a surface roughness of 10 angstroms or more;